News

October 17, 2017

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease (IBD) at the World Congress of Gastroenterology 2017, held in partnership with The American College of Gastroenterology in Orlando, Florida. The study was sponsored by ACT to corroborate published clinical trial results using native human AFP.

Download

June 15, 2017

Alpha Cancer Technologies Inc. Reports Acceptance of the Abstract of Study of ACT-101 in a Model of Inflammatory Bowel Disease to the World Congress of Gastroenterology at ACG 2017
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a pre-clinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.

Download

May 15, 2017

Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 Study Results in Pre-Clinical Model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.

Download

May 28, 2014

PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
Press Release

PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.

Download

March 11, 2014

Alpha Cancer To Test Oncology Game Changer
BioTuesdays

AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.

Read

January 15, 2014

Strength From Within
Bio Business

Despite seemingly daily reports of the newest wonder drug that shrinks tumours, gene therapies or even a vaccine there really hasn’t been much progress treating the disease over the last half-century. In 1960, the mortality rate for all cancers combined in the United States was 194 deaths per 100,000 people. In 2009, the mortality rate was 174 deaths for every 100,000 persons.

Download

July 23, 2012

Treatment Without Side Effects
National Post | Media Planet

Alpha Cancer Technologies Inc. (ACT) has created an innovative approach to the advancement of cancer care. Increasing the quality of life is one of the key advantages of a new chemotherapy delivery system that the company is advancing.

Download

January 25, 2011

The Pharma Company On A Path To Help Cancer Patients Beat Cancer
Technological Innovations In Life Sciences

The targeting concept is rational and conceptually very attractive – by carrying cytotoxic drugs selectively and specifically to targets on cancer cells, cancer cell killing should be increased and systemic toxicity should be reduced. However, as Dr. Sherman explained, success in this field has been hampered by four major obstacles…

Download